FM
EVOK

Family Management’s Evoke Pharma EVOK Stock Holding History

Family Management’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-72
Closed -$35K – 65
2017
Q3 		$35K Hold
72
– – 0.02% 67
2017
Q2 		$27K Hold
72
– – 0.02% 70
2017
Q1 		$32K Buy
+72
New +$29.5K 0.02% 70

Other funds holding EVOK

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BRF
B. Riley Financial Los Angeles, California $456M AUM 896.07% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Family Management's EVOK Position: Q4 2017 in Review

Family Management sold out of Evoke Pharma (EVOK) in Q4 2017, closing a stake of 72 shares — an estimated $35K sold.

Family Management first reported a position in EVOK in Q1 2017 and held it in 3 quarters. The position peaked at $35K in Q3 2017. 27 funds tracked by Wall St. Rank hold EVOK as of Q4 2017.

  • Family Management reported no remaining Evoke Pharma position as of Q4 2017 after selling out during the quarter.
  • Family Management sold 72 Evoke Pharma shares in Q4 2017, an estimated $35K.
  • Family Management first reported a position in Evoke Pharma in Q1 2017 and held it in 3 quarters.
  • Family Management's Evoke Pharma position peaked at $35K in Q3 2017.
  • 27 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2017.

Based on Family Management's 13F filing for Q4 2017, filed 15 Feb 2018.